Glenmark gets FDA nod for Voriconazole Tablets
September 04, 2015 | Friday | News | By BioSpectrum Bureau
Glenmark gets FDA nod for Voriconazole Tablets
Voriconazole Tablets are the the therapeutic equivalent of Vfend Tablets
Glenmark Pharmaceuticals (Glenmark) has been granted final approval by the United States Food and Drug Administration (US FDA) for Voriconazole Tablets, 50 mg and 200mg, the therapeutic equivalent of Vfend Tablets, 50 mg and 200 mg of PF Prism C.V. (Prism).
According to IMS Health sales data for the 12 month period ending July 2015, the Vfend market1 achieved annual sales of approximately $91.4 million.
Voriconazole is used in certain types of fungal infections.
